ARBOspot: Characterization of Arbovirus Specific T Cell Response in Patients by Using Enzyme Linked Immunospot (ELISpot) Assays
NCT07291206 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2026-03-04
Summary
Arboviruses (arthropod-borne viruses), are a group of RNA viruses that are transmitted to vertebrate hosts by hematophagous arthropods like mosquitos, ticks, and sandflies. In Italy, arboviruses pose a considerable public health concern because of their potential to infect humans and cause severe emergent or re-emergent diseases. Over the past few decades, arboviruses have already been responsible for epidemic outbreaks in Italy, and travels increase the risk of introducing new species previously confined to tropical and sub-tropical regions. Some arboviral infections, like West Nile Virus (WNV), Toscana Virus (TOSV), Sandfly Fever Sicily Virus (SFSV), Sandfly Fever Naples Virus (SFNV), Usutu Virus (USUV), and tick-borne encephalitis virus (TBEV), are considered endemic in Italy. Others, such as Chikungunya Virus (CHIKV), Dengue Virus (DENV), Zika Virus (ZIKV), Yellow Fever Virus (YFV) and Japanese encephalitis Virus (JEV) are under surveillance since imported infections could lead to local outbreaks and subsequent endemic circulation in Italy. Moreover, the increased global travel and unpredictable climate changes could facilitate the spread of arboviral infections. Adequate diagnostic tests play a crucial role in disease surveillance, identifying potential associations between previous infections and chronic diseases and controlling outbreaks by breaking transmission chains. Furthermore, immunological tests can help predict disease severity in healthy and immunocompromised subjects and identify patients at risk for severe disease during secondary infections.
In parallel with direct molecular diagnosis tests, the development of an immunological test capable of determining specific arbovirus T cell response may be useful for diagnostic as well as for epidemiological and investigative purposes. Furthermore, its development provides a set of initial knowledge on which to base the construction of other immunological tests for future emerging viruses, providing tools to counter new epidemic outbreaks. At the same time, the evaluation of immune response is necessary in order to control and contain the spread of these viruses. In conclusion, the present study aims to investigate immunological responses in patients infected with endemic arboviruses circulating in Italy those that could potentially emerging in the future.
Molecular tests have a reduced detectability window in biological samples, which is why often they are not useful for making a diagnosis. Serological tests can give cross-reactivity phenomena between some arboviruses, making differential diagnosis difficult and often inconclusive. Objective is to assess sensitivity of immunological assays for arboviruses-specific T Cell Response (ARBOspot) in order to use them in combination with conventional diagnostic methods.
Conditions
- Arbovirus Infections
Interventions
- DIAGNOSTIC_TEST
-
Immunological assays for charactarization of T-cell mediated response
ELISpot assay will be performed for monitoring of T-cell mediated response against arboviruses
- DIAGNOSTIC_TEST
-
Immunological assays
Immunological assays for characterization of T-cell mediated respone against arboviruses will be performed in follow-up
Sponsors & Collaborators
-
Fondazione IRCCS Policlinico San Matteo di Pavia
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-17
- Primary Completion
- 2026-12-31
- Completion
- 2027-12-31
Countries
- Italy
Study Locations
More Related Trials
-
Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine
NCT03055000 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine
NCT04009824 ·Status: COMPLETED ·Phase: PHASE1
-
A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
NCT04514107 ·Status: COMPLETED ·Phase: NA
-
Immune Responses After Human Subject Challenge With Sand Fly Bites
NCT01289977 ·Status: COMPLETED
-
Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults
NCT01624961 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults
NCT03110757 ·Status: COMPLETED ·Phase: PHASE1
-
Applying Wolbachia to Eliminate Dengue
NCT03055585 ·Status: TERMINATED ·Phase: NA
-
To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19
NCT05813587 ·Status: COMPLETED ·Phase: PHASE3
-
World Mosquito Program Noumea - Human Sample Component
NCT03552094 ·Status: UNKNOWN
-
Impact of Project Wolbachia - Singapore on Dengue Incidence
NCT05505682 ·Status: COMPLETED ·Phase: NA
-
Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires
NCT01214876 ·Status: COMPLETED
-
Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria
NCT00075049 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.
NCT00197054 ·Status: COMPLETED ·Phase: PHASE2
-
Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP
NCT06881732 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults
NCT06862453 ·Status: RECRUITING ·Phase: PHASE1
-
Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali
NCT05135273 ·Status: COMPLETED ·Phase: PHASE1
-
Rickettsiae in Myanmar
NCT03847870 ·Status: COMPLETED
-
Impact of IIT-SIT on Dengue Clusters
NCT06894901 ·Status: RECRUITING ·Phase: NA
-
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
NCT06735209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
NCT06268691 ·Status: COMPLETED ·Phase: NA
-
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
NCT03303898 ·Status: COMPLETED ·Phase: NA
-
Experimental PfSPZ Vaccine in Adults Without Malaria
NCT01441167 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
NCT01154049 ·Status: COMPLETED ·Phase: PHASE1
-
Innovative Multidisciplinary Strategies for Combating Severe Dengue
NCT06751836 ·Status: RECRUITING
-
Factors Associated With Hospitalization and Severity of Arbovirosis in the Indian Ocean
NCT07119086 ·Status: RECRUITING ·Phase: NA